Parwez Ahmad1, Jiri Sana1,2, Marek Slavik3, Dominik Gurin4, Lenka Radova1, Natalia Anna Gablo1, Tomas Kazda3, Pavel Smilek5, Zuzana Horakova5, Bretislav Gal5, Marketa Hermanova4, Pavel Slampa3, Ondrej Slaby6,2. 1. Central European Institute of Technology, Masaryk University, Brno, Czech Republic. 2. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 3. Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic. 4. 1st Department of Pathology, St. Anne's University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic. 5. Department of Otorhinolaryngology and Head and Neck Surgery, St. Anne's University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic. 6. Central European Institute of Technology, Masaryk University, Brno, Czech Republic on.slaby@gmail.com.
Abstract
BACKGROUND/AIM: Head and neck cancers are a heterogenous group of epithelial tumors represented mainly by squamous cell carcinomas (HNSCC), which are the sixth most common type of cancer worldwide. Surgery together with radiotherapy (RT) is among the basic treatment modalities for most HNSCC patients. Various biomarkers aiming to predict patients' response to RT are currently investigated. The reason behind this effort is, on one hand, to distinguish radioresistant patients that show weak benefit from RT and, on the other hand, reduce the ionizing radiation dose in less aggressive radiosensitive HNSCC with possibly less acute or late toxicity. MATERIALS AND METHODS: A total of 94 HNSCC patients treated by definitive intensity-modulated radiotherapy were included in our retrospective study. We used a global expression analysis of microRNAs (miRNAs) in 43 tumor samples and validated a series of selected miRNAs in an independent set of 51 tumors. RESULTS: We identified miR-15b-5p to be differentially expressed between patients with short and long time of locoregional control (LRC). Kaplan-Meier analysis confirmed that HNSCC patients with higher expression of miR-15b-5p reach a significantly longer locoregional relapse-free survival compared to patients expressing low levels. Finally, multivariable Cox regression analysis revealed that miR-15b-5p is an independent predictive biomarker of LRC in HNSCC patients (HR=0.25; 95% CI=0.05-0.78; p<0.016). CONCLUSION: miR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCC patients. Copyright
BACKGROUND/AIM: Head and neck cancers are a heterogenous group of epithelial tumors represented mainly by squamous cell carcinomas (HNSCC), which are the sixth most common type of cancer worldwide. Surgery together with radiotherapy (RT) is among the basic treatment modalities for most HNSCCpatients. Various biomarkers aiming to predict patients' response to RT are currently investigated. The reason behind this effort is, on one hand, to distinguish radioresistant patients that show weak benefit from RT and, on the other hand, reduce the ionizing radiation dose in less aggressive radiosensitive HNSCC with possibly less acute or late toxicity. MATERIALS AND METHODS: A total of 94 HNSCCpatients treated by definitive intensity-modulated radiotherapy were included in our retrospective study. We used a global expression analysis of microRNAs (miRNAs) in 43 tumor samples and validated a series of selected miRNAs in an independent set of 51 tumors. RESULTS: We identified miR-15b-5p to be differentially expressed between patients with short and long time of locoregional control (LRC). Kaplan-Meier analysis confirmed that HNSCCpatients with higher expression of miR-15b-5p reach a significantly longer locoregional relapse-free survival compared to patients expressing low levels. Finally, multivariable Cox regression analysis revealed that miR-15b-5p is an independent predictive biomarker of LRC in HNSCCpatients (HR=0.25; 95% CI=0.05-0.78; p<0.016). CONCLUSION:miR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCCpatients. Copyright
Authors: L Sun; Y Yao; B Liu; Z Lin; L Lin; M Yang; W Zhang; W Chen; C Pan; Q Liu; E Song; J Li Journal: Oncogene Date: 2011-07-04 Impact factor: 9.867
Authors: Nicole L Simone; Benjamin P Soule; David Ly; Anthony D Saleh; Jason E Savage; William Degraff; John Cook; Curtis C Harris; David Gius; James B Mitchell Journal: PLoS One Date: 2009-07-27 Impact factor: 3.240
Authors: Felix Zwicker; Benedict Swartman; Peter E Huber; Klaus Herfarth; Jürgen Debus; Henrik Hauswald Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155